JP2004527494A5 - - Google Patents

Download PDF

Info

Publication number
JP2004527494A5
JP2004527494A5 JP2002567337A JP2002567337A JP2004527494A5 JP 2004527494 A5 JP2004527494 A5 JP 2004527494A5 JP 2002567337 A JP2002567337 A JP 2002567337A JP 2002567337 A JP2002567337 A JP 2002567337A JP 2004527494 A5 JP2004527494 A5 JP 2004527494A5
Authority
JP
Japan
Prior art keywords
medicament
endostatin
retinal
choroidal
microcapsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002567337A
Other languages
English (en)
Other versions
JP2004527494A (ja
JP4689144B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/005336 external-priority patent/WO2002067971A2/en
Publication of JP2004527494A publication Critical patent/JP2004527494A/ja
Publication of JP2004527494A5 publication Critical patent/JP2004527494A5/ja
Application granted granted Critical
Publication of JP4689144B2 publication Critical patent/JP4689144B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Claims (27)

  1. 眼球血管新生に罹患した個体の眼組織中のエンドスタチンの量を眼球血管新生阻害有効量へ高めることができる、眼球血管新生処置用医薬
  2. エンドスタチンが配列番号1に示すアミノ酸配列を有するポリペプチドである、請求項1の医薬
  3. エンドスタチンが配列番号1に示すアミノ酸配列を有するポリペプチドのポリペプチドフラグメント、配列番号1に示すアミノ酸配列を有するポリペプチドの誘導体、または配列番号1に示すアミノ酸配列を有するポリペプチドの変異体である、請求項1の医薬
  4. ンドスタチンが個体にとって外生(exogenous)である、請求項1〜3の何れかの医薬
  5. エンドスタチンコード核酸を含むウイルスベクターを含有する、眼球血管新生処置用医薬
  6. ウイルスベクターがアデノウイルス、アデノ随伴ウイルス、レトロウイルスおよびレンチウイルスからなる群より選択される、請求項医薬
  7. ウイルスベクターがアデノウイルスベクターである、請求項医薬
  8. エンドスタチンを分泌するセルを含む、個体内にインプラントするためのマイクロカプセル。
  9. マイクロカプセルがアルギン酸塩を含む、請求項マイクロカプセル
  10. マイクロカプセルがアルギン酸ナトリウムを含む、請求項マイクロカプセル
  11. マイクロカプセルがアルギン酸カルシウムを含む、請求項10マイクロカプセル
  12. マイクロカプセルがポリL−リジンを含む、請求項11マイクロカプセル
  13. セルが外生エンドスタチンコード核酸を含む請求項マイクロカプセル
  14. セルが外生エンドスタチンコード遺伝子を過剰発現する、請求項マイクロカプセル
  15. ベクターが1プラーク形成単位ないし114プラーク形成単位で存在する、請求項医薬
  16. ベクターが1プラーク形成単位ないし114プラーク形成単位で存在する、請求項医薬
  17. エンドスタチンコード核酸が配列番号2に示す配列を有する、請求項医薬
  18. 眼球血管新生がヒストプラズマ症、病的近視、網膜色素線条、前部虚血性視神経症、細菌性心内膜炎、Best病、birdshot網膜脈絡膜病、脈絡膜血管腫、脈絡膜母斑、脈絡膜非潅流、脈絡膜骨腫、脈絡膜破裂、先天性脈絡膜欠如、慢性網膜剥離、網膜の欠損、ドルーゼ、内因性カンジダ眼内炎、網膜色素上皮の過剰乳頭状過誤腫、黄色斑眼底、特発性、黄斑円孔、悪性黒色腫、膜増殖性糸球体腎炎(II型)、金属性眼内異物、朝顔円盤症候群、多発性一過性白点症候群(MEWDS)、鋸状炎の血管新生、手術顕微鏡熱傷、視神経頭小窩、光凝固術、斑点状内部脈絡膜症、風疹、類肉腫症、蛇行性または地図状脈絡膜症、網膜下排液、傾斜性椎間板症候群、トキソプラズマ網脈絡膜炎、結核、Vogt-Koyanagi-Harada症候群、糖尿病性網膜症、非糖尿病性網膜症、枝静脈閉塞、中枢網膜静脈閉塞、未成熟幼児の網膜症、虹彩ルベオシス、新生血管緑内障、perifoveal網膜血管拡張症、鎌状細胞網膜症、Eale病、網膜脈管炎、Von Hippel Lindau病、放射線網膜症、網膜凍傷、色素性網膜症、網脈絡膜欠損症、単純ヘルペス角膜炎、角膜潰瘍、角膜移植、pterigyiaおよび外傷からなる群より選択される因子によって引き起こされている、請求項1の医薬
  19. 眼球血管新生が脈絡膜血管新生である、請求項18医薬
  20. 眼内投与のための、請求項5の医薬。
  21. 網膜下投与のための、請求項20の医薬
  22. 硝子体内投与のための、請求項20の医薬。
  23. ウイルスベクターがレンチウイルスベクターである、請求項医薬
  24. レンチウイルスベクターがウシ免疫不全ウイルスベクターである、請求項23医薬
  25. 眼内投与のための、請求項24の医薬。
  26. 網膜下投与のための、請求項25の医薬。
  27. 硝子体内投与のための、請求項26の医薬。
JP2002567337A 2001-02-22 2002-02-21 眼球血管新生を処置するための方法 Expired - Lifetime JP4689144B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27078701P 2001-02-22 2001-02-22
US60/270,787 2001-02-22
US28129601P 2001-04-04 2001-04-04
US60/281,296 2001-04-04
PCT/US2002/005336 WO2002067971A2 (en) 2001-02-22 2002-02-21 Use of endostatin in the treatment of ocular neovascularization

Publications (3)

Publication Number Publication Date
JP2004527494A JP2004527494A (ja) 2004-09-09
JP2004527494A5 true JP2004527494A5 (ja) 2006-01-05
JP4689144B2 JP4689144B2 (ja) 2011-05-25

Family

ID=26954498

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002567337A Expired - Lifetime JP4689144B2 (ja) 2001-02-22 2002-02-21 眼球血管新生を処置するための方法

Country Status (5)

Country Link
US (3) US20020183253A1 (ja)
EP (1) EP1401480B1 (ja)
JP (1) JP4689144B2 (ja)
AU (1) AU2002240463A1 (ja)
WO (1) WO2002067971A2 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234505A1 (en) * 1998-09-23 2004-11-25 Stuart Naylor Polynucleotide constructs and uses thereof
US7122181B2 (en) * 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
EP1401480B1 (en) 2001-02-22 2012-11-28 Novartis AG Viral vectors encoding endostatin in the treatment of ocular neovascularization
US6875165B2 (en) 2001-02-22 2005-04-05 Retinalabs, Inc. Method of radiation delivery to the eye
WO2003066810A2 (en) * 2002-02-04 2003-08-14 Novartis Ag Recombinant bovine immunodeficiency virus based gene transfer system
CA2480809A1 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
DE60332122D1 (de) * 2002-08-28 2010-05-27 Novartis Ag Gentherapie des auges
US20060251621A1 (en) * 2002-09-27 2006-11-09 Campochiaro Peter A Ocular gene therapy
GB0402100D0 (en) * 2004-01-30 2004-03-03 Novartis Ag Organic compounds
WO2005079915A1 (en) 2004-02-12 2005-09-01 Neo Vista, Inc. Methods and apparatus for intraocular brachytherapy
US7803103B2 (en) 2005-02-11 2010-09-28 Neovista Inc. Methods and apparatus for intraocular brachytherapy
DK1767545T3 (da) 2005-09-22 2010-03-15 Biocompatibles Uk Ltd GLP-1 (Glucagon-lignende peptid-1)-fusionspolypeptider med forøget peptidaseresistens
ATE444741T1 (de) 2006-05-10 2009-10-15 Biocompatibles Uk Ltd Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
US8353812B2 (en) 2008-06-04 2013-01-15 Neovista, Inc. Handheld radiation delivery system
EP2251028A1 (en) * 2009-05-12 2010-11-17 Biocompatibles Uk Ltd. Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor
CN104548067A (zh) * 2014-12-23 2015-04-29 浙江省人民医院 重组人血管内皮抑制素在制备治疗眼表新生血管性疾病药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545423A (en) * 1991-11-25 1996-08-13 Vivorx, Inc. Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials
WO1994012161A1 (en) * 1992-11-24 1994-06-09 Clover Consolidated, Limited Cytoprotective, biocompatible, retrievable macrocapsules
US5827702A (en) * 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
CN1202932A (zh) * 1995-10-23 1998-12-23 儿童医学中心公司 治疗用抗血管生成的组合物和方法
US6174861B1 (en) * 1996-10-22 2001-01-16 The Children's Medical Center Corporation Methods of inhibiting angiogenesis via increasing in vivo concentrations of endostatin protein
WO1998049321A2 (en) * 1997-04-28 1998-11-05 Rhone-Poulenc Rorer S.A. Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
WO1999015641A1 (en) * 1997-09-24 1999-04-01 The Regents Of The University Of California Non-primate lentiviral vectors and packaging systems
WO1999026480A1 (en) * 1997-11-20 1999-06-03 Genetix Pharmaceuticals, Inc. Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
US6201104B1 (en) * 1998-12-04 2001-03-13 Entremed, Inc. Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
IT1312077B1 (it) * 1999-04-15 2002-04-04 Univ Degli Studi Milano Polipeptidi ad attivita' antiangiogenica.
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
US7125542B2 (en) * 2000-02-10 2006-10-24 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
AU2002224403A1 (en) * 2000-10-13 2002-04-22 Entremed, Inc Endostatin and pitslre protein kinases as angiogenesis-inhibiting peptides and method of use
RU2288742C2 (ru) 2000-12-19 2006-12-10 Рисерч Дивелопмент Фаундейшн Перенос генов, опосредованный лентивирусным вектором, и их использование
US7122181B2 (en) 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
EP1401480B1 (en) 2001-02-22 2012-11-28 Novartis AG Viral vectors encoding endostatin in the treatment of ocular neovascularization

Similar Documents

Publication Publication Date Title
JP2004527494A5 (ja)
Reichel et al. Immune responses limit adenovirally mediated gene expression in the adult mouse eye
US8338384B2 (en) Method for treating ocular neovascularization
US7989426B2 (en) Selective induction of apoptosis to treat ocular disease by expression of PEDF
US20070098692A1 (en) Materials and methods for treating ocular-related disorders
EP1463531B1 (en) Methods for inhibiting ocular processes
Klausner et al. Corneal gene therapy
US20090011040A1 (en) Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
Hauswirth et al. Ocular gene therapy: quo vadis?
Liu et al. Gene therapy targeting glaucoma: where are we?
US11739130B2 (en) Delivery of card protein as therapy for ocular inflammation
US20140005257A1 (en) Methods of gene therapy for treating disorders of the ear by administering a vector encoding an atonal-associated factor
AU2003297607A1 (en) Materials and methods for treating ocular-related disorders
AU780634C (en) Gene Therapy for treating ocular-related disorders
US20080227692A1 (en) Compositions and methods for treating ophthalmic disorders
JP2007528903A (ja) 眼における血管漏出を処置するための物質
US20070232541A1 (en) Methods of regulating angiogenisis through stabilization of pedf
Liu et al. Ocular drug delivery: molecules, cells, and genes
Ali et al. Co-injection of adenovirus expressing CTLA4-Ig prolongs adenovirally mediated lacZ reporter gene expression in the mouse retina
US20030170209A1 (en) Use of a vector comprising a nucleic acid coding for an anti-angiogenic factor for treating corneal neovascularization
US20080107714A1 (en) Use of a vector comprising a nucleic acid encoding an anti-angiogenic factor for the treatment of corneal neovascularization
WO2013067133A1 (en) Production of tsg-6 protein
CN117089560A (zh) 融合核酸、腺相关病毒载体及其用途和药物制剂
US20200179482A1 (en) Composition for and method of facilitating corneal tissue repair
JP2023531289A (ja) 眼病態の処置のためのdna構造